Sign inJoin Free
DashboardSign out
Clinical Research Coordinator
Full course · Safety Reporting and Pharmacovigilance for CRCs
Clinical Research Coordinator
Full course · Safety Reporting and Pharmacovigilance for CRCs
Free Lesson Preview
Module 1: Lesson 1
Understand how expectedness is assessed against the Investigator's Brochure reference safety information and why accurate event description by the CRC enables this critical determination.
A conceptual hero image depicting the Investigator's Brochure as the definitive reference point for adverse event expectedness. An open reference document occupies the center of the composition, with listed safety terms radiating outward. To one side, a reported clinical event -- rendered in sharp, specific detail -- is being compared against the listed terms. The visual tension lies in whether the event matches the listed terms or falls outside the documented profile. A subtle magnifying lens suggests the precision required to distinguish a listed category from an unlisted specific manifestation. The mood conveys careful, consequential analysis rather than routine paperwork.
A participant in a Phase II hepatology trial reports persistent nausea after three weeks on the investigational agent. The coordinator reviews the source documents, confirms the onset and severity, and documents the event. The Investigator's Brochure lists nausea among the known adverse reactions, observed in 18% of participants during the Phase I program. Nausea: expected.
Two days later, the same participant's routine laboratory panel returns with alanine aminotransferase at 11 times the upper limit of normal. The investigator reviews the result, confirms it is clinically significant, and the coordinator documents the event as hepatotoxicity. The coordinator reaches for the Investigator's Brochure again. The IB's safety section lists "transaminase elevation" as a known finding. But the participant's clinical picture -- markedly elevated transaminases with early signs of synthetic dysfunction -- may represent a severity and specificity that goes beyond the mild, transient elevations described in the IB. Is this expected?
That question -- seemingly simple, fundamentally consequential -- determines whether this event is classified as a Suspected Unexpected Serious Adverse Reaction. And that classification triggers a cascade: expedited reporting to regulatory authorities, notification to all investigators worldwide, potential protocol amendments, possible trial suspension. The difference between "expected" and "unexpected" is not a matter of semantics. It is the fulcrum on which the most urgent safety reporting obligations pivot.
This lesson teaches you what expectedness means, where to find the reference document that defines it, and -- critically -- whose job it is to make the determination. The CRC does not decide expectedness. But the CRC's documentation is what makes accurate expectedness assessment possible.
Free Lesson Preview
Module 1: Lesson 1
Understand how expectedness is assessed against the Investigator's Brochure reference safety information and why accurate event description by the CRC enables this critical determination.
A conceptual hero image depicting the Investigator's Brochure as the definitive reference point for adverse event expectedness. An open reference document occupies the center of the composition, with listed safety terms radiating outward. To one side, a reported clinical event -- rendered in sharp, specific detail -- is being compared against the listed terms. The visual tension lies in whether the event matches the listed terms or falls outside the documented profile. A subtle magnifying lens suggests the precision required to distinguish a listed category from an unlisted specific manifestation. The mood conveys careful, consequential analysis rather than routine paperwork.
A participant in a Phase II hepatology trial reports persistent nausea after three weeks on the investigational agent. The coordinator reviews the source documents, confirms the onset and severity, and documents the event. The Investigator's Brochure lists nausea among the known adverse reactions, observed in 18% of participants during the Phase I program. Nausea: expected.
Two days later, the same participant's routine laboratory panel returns with alanine aminotransferase at 11 times the upper limit of normal. The investigator reviews the result, confirms it is clinically significant, and the coordinator documents the event as hepatotoxicity. The coordinator reaches for the Investigator's Brochure again. The IB's safety section lists "transaminase elevation" as a known finding. But the participant's clinical picture -- markedly elevated transaminases with early signs of synthetic dysfunction -- may represent a severity and specificity that goes beyond the mild, transient elevations described in the IB. Is this expected?
That question -- seemingly simple, fundamentally consequential -- determines whether this event is classified as a Suspected Unexpected Serious Adverse Reaction. And that classification triggers a cascade: expedited reporting to regulatory authorities, notification to all investigators worldwide, potential protocol amendments, possible trial suspension. The difference between "expected" and "unexpected" is not a matter of semantics. It is the fulcrum on which the most urgent safety reporting obligations pivot.
This lesson teaches you what expectedness means, where to find the reference document that defines it, and -- critically -- whose job it is to make the determination. The CRC does not decide expectedness. But the CRC's documentation is what makes accurate expectedness assessment possible.
This is just the beginning
The full CRC track covers 8 courses from study start-up to close-out — the skills sponsors actually look for.
Start the CRC trackThis is just the beginning
The full CRC track covers 8 courses from study start-up to close-out — the skills sponsors actually look for.
Start the CRC track